- Home
- CET vs TXG Comparison
CET vs TXG Comparison
Compare CET & TXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CET
- TXG
- Stock Information
- Founded
- CET 1929
- TXG 2012
- Country
- CET United States
- TXG United States
- Employees
- CET N/A
- TXG N/A
- Industry
- CET Finance/Investors Services
- TXG Biotechnology: Laboratory Analytical Instruments
- Sector
- CET Finance
- TXG Industrials
- Exchange
- CET Nasdaq
- TXG Nasdaq
- Market Cap
- CET 1.2B
- TXG 1.0B
- IPO Year
- CET N/A
- TXG 2019
- Fundamental
- Price
- CET $46.61
- TXG $9.53
- Analyst Decision
- CET
- TXG Buy
- Analyst Count
- CET 0
- TXG 15
- Target Price
- CET N/A
- TXG $15.81
- AVG Volume (30 Days)
- CET 22.7K
- TXG 3.7M
- Earning Date
- CET 01-01-0001
- TXG 05-08-2025
- Dividend Yield
- CET 4.84%
- TXG N/A
- EPS Growth
- CET 26.33
- TXG N/A
- EPS
- CET 9.95
- TXG N/A
- Revenue
- CET $23,698,535.00
- TXG $624,662,000.00
- Revenue This Year
- CET N/A
- TXG N/A
- Revenue Next Year
- CET N/A
- TXG $6.74
- P/E Ratio
- CET $4.67
- TXG N/A
- Revenue Growth
- CET 11.75
- TXG N/A
- 52 Week Low
- CET $40.24
- TXG $6.78
- 52 Week High
- CET $49.51
- TXG $24.76
- Technical
- Relative Strength Index (RSI)
- CET 60.83
- TXG 58.21
- Support Level
- CET $45.77
- TXG $8.07
- Resistance Level
- CET $46.91
- TXG $9.42
- Average True Range (ATR)
- CET 0.68
- TXG 0.50
- MACD
- CET -0.06
- TXG 0.06
- Stochastic Oscillator
- CET 49.43
- TXG 84.93
About CET Central Securities Corporation
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
About TXG 10x Genomics Inc.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).